To Treat or Not to Treat: Management Options for Symptomatic Vitreous Floaters

被引:10
|
作者
Broadhead, Geoffrey K. [1 ,2 ]
Hong, Thomas [2 ,3 ]
Chang, Andrew A. [1 ,2 ,3 ]
机构
[1] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia
[2] Sydney Inst Vis Sci, Level 13,187 Macquarie St, Sydney, NSW 2000, Australia
[3] Sydney Retina Clin & Day Surg, Sydney, NSW, Australia
来源
关键词
asteroid hyalosis; posterior vitreous detachment; vitrectomy; vitreous floaters; YAG vitreolysis; PARS-PLANA VITRECTOMY; VISUAL-ACUITY SECONDARY; YAG LASER VITREOLYSIS; ASTEROID HYALOSIS; RETINAL BREAKS; SUTURELESS VITRECTOMY; CONTRAST SENSITIVITY; CATARACT-SURGERY; 25-GAUGE; SAFETY;
D O I
10.1097/APO.0000000000000276
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Vitreous floaters are a common cause for presentation to ophthalmologists, and may significantly affect visual function. In the absence of some more serious underlying pathology such as uveitis, many patients may not experience significant persistent visual impairment from floaters. For some patients, the symptomatic effects of floaters may persist. For these patients, treatment options are available, of which the most commonly reported is vitrectomy. Other treatment modalities have also become more common, notably YAG vitreolysis. Selection of appropriate patients for surgery is often difficult, in part due to the relative lack of objective outcomes with which to measure both visual impairment and improvement post-procedure. Although well-tolerated, vitrectomy does carry with it risks, including iatrogenic retinal breaks, retinal detachment, and in phakic patients, subsequent cataract formation. Techniques such as small gauge vitrectomy, intraoperative examination and treatment of breaks or other worrying lesions, and careful consideration of the need for posterior vitreous detachment induction may help limit the incidence of these adverse events. For other treatment options such as YAG vitreolysis, research and clinical experience remain more limited, and as such the long-term efficacy and risks of these therapies are still unclear. Here, we review the evidence surrounding the role of vitrectomy and YAG vitreolysis in the treatment of vitreous floaters and potential means to minimize therapeutic complications.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [41] Vitrectomy for vitreous floaters
    Ascaso, F.
    ACTA OPHTHALMOLOGICA, 2016, 94
  • [42] New options to treat influenza B
    Aeron C. Hurt
    Kanta Subbarao
    Nature Microbiology, 2017, 2 : 1342 - 1343
  • [43] To Treat or not to Treat? The Fate of Patients with Intermittent Claudication Following Different Therapeutic Options
    Tsolaki, Elpiniki
    Traina, Luca
    Savrie, Caterina
    Guerzoni, Franco
    Napoli, Nicola
    Manfredini, Roberto
    Taddia, Maria Cristina
    Manfredini, Fabio
    Lamberti, Nicola
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (06)
  • [44] New options to treat influenza B
    Hurt, Aeron C.
    Subbarao, Kanta
    NATURE MICROBIOLOGY, 2017, 2 (10): : 1342 - 1343
  • [45] Laser for vitreous floaters
    Tassignon, M. J.
    ACTA OPHTHALMOLOGICA, 2016, 94
  • [46] Management of Small Unruptured Intracranial Aneurysms To Treat or Not to Treat?
    Elkun, Yuval
    Cooper, Jared
    Kamal, Haris
    Dakay, Katarina
    Nuoaman, Halla
    Adnan, Yasir Ammar
    Dodson, Vincent
    Nuoman, Rolla
    Kaur, Kavneet
    Kurian, Christeena
    Sahni, Ramandeep
    Gandhi, Chirag
    Al-Mufti, Fawaz
    CARDIOLOGY IN REVIEW, 2021, 29 (01) : 33 - 38
  • [47] Subclinical Hypothyroidism: Management in Primary Care - To treat or not to treat?
    Sumathipala, Sanjeewa
    WORLD FAMILY MEDICINE, 2021, 19 (01): : 151 - 156
  • [48] THE INCIDENCE OF PREVIOUS POSTERIOR VITREOUS DETACHEMENT IN PATIENTS UNDERGOING PARS PLANA VITRECTOMY FOR RESOLUTION OF SYMPTOMATIC VITREOUS FLOATERS
    Kirchner, Ian
    Ellenberg, David
    Scharper, Philip Henry
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [49] Objective assessment of symptomatic vitreous floaters using optical coherence tomography: a case report
    Kevin Patrick Kennelly
    James Plunkett Morgan
    David Jude Keegan
    Paul Patrick Connell
    BMC Ophthalmology, 15
  • [50] The benefit of nonpharmacologic therapy to treat symptomatic osteoarthritis
    Lee Y.C.
    Shmerling R.H.
    Current Rheumatology Reports, 2008, 10 (1) : 5 - 10